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Abstract
Background: Improvement of neurologic outcome in progesterone-administered patients with diffuse axonal injury (DAI) has
been found in a recent study. Also, there has been interest in the importance of serum parameters as predictors of outcome in
traumatic brain injury.
Objectives: The aim of this study was to examine the effect of progesterone administration on serum levels of neuron-specific
enolase (NSE), and intercellular adhesion molecule-1 (ICAM-1) in clinical DAI.
Patients andMethods: In this study, the serum levels of ICAM-1 and NSE of 32 male DAI patients (18 - 60 years of age, a Glasgow coma
scale of 12 or less, and admitted within 4 hours after injury) who were randomized for a controlled phase II trial of progesterone were
analyzed. The analysis was performed between the control and progesterone groups at admission time, and 24 hours and six days
after DAI, respectively.
Results: A reduction in the serum level of ICAM-1 was noticed in the progesterone group 24 hours after the injury (P < 0.05). There
was no significant difference in the serum level of NSE between the study groups during evaluation. At 24 hours after the injury, the
level of ICAM-1 in the control group was higher than that at admission time (P < 0.05). The lowest level of NSE in the two groups was
seen six days after DAI (P < 0.01).
Conclusions: In summary, progesterone administration reduced serum ICAM-1, and whereby may attenuate blood brain barrier
disruption, the latter needs further investigation for confirmation.
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1. Background
Traumatic brain injury (TBI) is a major cause of death
and disability (1), and there are no currently treatments
that improve clinical outcome (2). Progesterone as a
reproduction-related hormone exerts anti-oxidative, anti-
apoptotic, and anti-inflammatory effects in the nervous
system (3). Experimental studies have suggested that pro-
gesterone is a promising neuroprotective agent in TBI (4-
6), but analyses of phase III clinical trials with proges-
terone have not been shown to be successful on functional
outcome (7, 8). This failure may be due to the lack of eval-
uating biomarkers relevant to TBI (9). Thus, the evaluation
of serum markers may help the diagnosis of improvement
following an intervention in a minimally invasive manner.
The search for predictive markers of outcome in TBI has
been begun over 20 years ago. The evaluation of biomark-
ers in TBI patients could help the intervention selection,
and provide the prognostic information (1).
Pathophysiology of TBI is a complex interplay of brain
specific proteins, and cytokine-mediated immune reac-
tions (10). Inflammation has a great role in the patho-
physiology of TBI (11). Interleukin-1β (IL-1β), tumor necro-
sis factor (TNF-α), and IL-6, which are released within min-
utes of the primary injury, can cause the infiltration of in-
flammatory cells into the brain by activating intercellu-
lar adhesion molecule-1 (ICAM-1) (12). It has been shown
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that cerebrospinal fluid (CSF) concentration of ICAM-1 indi-
cates tissue and blood-brain barrier (BBB) damage, giving
an indication of the immunologic reaction in the injured
brain (13). Also, the increase in serum neuron-specific eno-
lase (NSE) correlates with the injury of neurons (14). The
neuron-specific enolase is one of its five isoenzymes of gly-
colytic enolase (15) and involved during the onset of neu-
ronal activity. The neuron-specific enolase can be useful as
a serum biomarker in diffuse axonal injury (DAI) (14).
The inhibition of ICAM-1 expression in the injured
brain has been revealed by progesterone administration
at five days after experimental TBI (16). Progesterone ad-
ministration led to decreasing ICAM-1 expression at 48
hours after subarachnoid hemorrhage (SAH) (17). Proges-
terone treatment attenuated significantly markers of neu-
roinflammation in TBI rats, concomitant with reduction in
neurologic impairments (18).
In our previous study, progesterone-administered DAI
patients showed decreasing IL-1β, and increasing IL-6 and
transforming growth factor-β1 (TGF-β1) in serum. Also, the
serum level of malondialdehyde (MDA), as an indication of
lipid peroxidation was reduced in them (19). However, the
neuroprotective effect of progesterone on serum levels of
NSE and ICAM-1 has not been investigated in clinical trial.
2. Objectives
The present study aimed to examine the effect of
progesterone administration on serum levels of NSE and
ICAM-1 in DAI patients of a randomized controlled phase
II trial of progesterone. We hypothesized that modulat-
ing the pathophysiological pathways related to cerebral
inflammation after TBI by progesterone is a mechanism
whereby progesterone protects neurons, and improves
neurologic outcome after TBI.
3. Patients andMethods
3.1. The Study Patients
This study was part of a single- center blinded, random-
ized, controlled phase II trial of progesterone that a part of
the results of trial has been published (19). The approval
of the trial protocol was obtained from the ethics com-
mittee of Kerman University of Medical Sciences (K/92/579)
prior to the commencement of the trial. The trial was
registered in Iranian registry of clinical trials (www.irct.ir,
CT2014042017356N1). The eligibility criteria of trial were
male, Glasgow coma scale (GCS) of 12 or less, pure DAI using
a computed tomography (CT) scan, admission within four
hours after injury, and 18 to 60 years of age. The patients
of trial were randomly placed in either the case (received
progesterone) or control group. The trial was executed in
trauma center of Kerman province.
The case group received progesterone intramuscularly
1 mg/kg/12 hours for five days. All of the study patients re-
ceived the standard management protocol for TBI (19).
Blood samples obtained at three time points (admis-
sion, and 24 hours and six days after the study) were ana-
lyzed to measure the ICAM-1 and NSE levels (19).
3.2. The Measurement of Serum Levels of Intercellular Adhesion
Molecule-1 and Neuron-Specific Enolase
The serum levels of ICAM-1 (sensitivity range 31.3 - 2000
pg/mL, R and D) and NSE (sensitivity range 0.31 - 20 ng/mL,
R and D) were assessed using commercially available
enzyme- linked immunosorbent assay (ELISA) kits. Briefly,
a quantitative assay of these variables was done using the
secondary antibody labeled with peroxidase and produc-
ing colored product to read in a spectrophotometer. A stan-
dard curve was prepared for any biomarker using respec-
tive standards, and the serum levels of biomarkers were de-
termined using the respective standard curve. The serum
levels of ICAM-1 and NSE were expressed as picograms per
milliliter (pg/mL) and nanograms per milliliter (ng/mL),
respectively.
3.3. Statistical Analysis
The data were expressed as mean± SEM. SPSS 20 soft-
ware was used to analyze data. The data normality was
checked by Shapiro-Wilk’s test. The comparison of the vari-
ables among the times was performed using two-way re-
peated measures ANOVA. The comparison between the two
groups was performed by two independent t-tests. A value
of P < 0.05 was considered to be statistically significant.
4. Results
4.1. The Study Patients
No significant difference was found regarding age, in-
jury time to randomization, severity of injury and cause of
DAI between the two groups (Table 1).
4.2. The Serum Level of Intercellular Adhesion Molecule-1 in Dif-
fuse Axonal Injury Patients Following Progesterone Administra-
tion
The effect of progesterone on the serum level of ICAM-
1 in DAI patients has shown in Table 2. No significant dif-
ference was found in the ICAM-1 level between the control
and progesterone groups at the time of admission and six
days after injury (P = 0.21 and P = 0.77, respectively). In
contrast, 24 hours after the injury, the ICAM-1 level was re-
duced in the progesterone group (868.97± 166.54 pg/mL)
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Table 1. The Clinical and Demographic Characteristics of the Study Groups at the Admission Time
Characteristics Control (n = 16) Progesterone (n = 16) P Value
Age, y;mean± SEM 30.75± 3.4 28.44± 1.74 0.84
Injury time to randomization (minute);mean± SEM 84.81± 9.93 69.36± 19.38 0.98
GCS (score);mean± SEM
Total 7.75± 0.52 7.5± 0.55 0.81
Cause of DAI, No. (%) N/S
Motor vehicle 15 (93.8) 16 (100)
Fall 0 (0.0) 0 (0.0)
Other 1 (6.2) 0 (0.0)
Abbreviations: DAI, diffuse axonal injury; GCS, Glasgow coma scale; N/S, not significant; n, number of patients.
compared to the control group (1422.96± 203.87 pg/ mL)
(P < 0.05). The amount of reduction in the progesterone
group in comparison with the control group was 38.95% at
24 hours after the injury. An increase in the ICAM-1 level was
found in the control group at 24 hours in comparison to
the admission time (P < 0.05).
Table 2. The Effect of Progesterone on the Serum Level of Intercellular Adhesion
Molecule-1 (pg/ mL) in Diffuse Axonal Injury Patients







Admission time 829.47± 93.31 990.52± 83.2 0.21
24 hours after
injury
1422.96± 203.87a 868.97± 166.54b 0.04
6 days after
injury
865.81± 193.61 939.61± 151.55 0.77
aP < 0.05 vs. admission in the control group.
bP < 0.05 vs. control group at 24 hours after the injury.
4.3. The Serum Level of Neuron-Specific Enolase in Diffuse Ax-
onal Injury Patients Following Progesterone Administration
The effect of progesterone on the serum level of NSE in
DAI patients has shown in Table 3. No significant difference
was found in the NSE level between the control and proges-
terone groups during assay (P = 0.42, P = 0.58 and P = 0.1,
respectively). A significant decrease was found in the NSE
level in the control and progesterone groups six days after
the injury in comparison to admission and 24 h after the
injury (P < 0.01).
5. Discussion
To our knowledge, the current study is the first study to
examine the effect of progesterone administration on the
Table 3. The Effect of Progesterone on the Serum Level of Neuron-Specific Enolase
(ng/ mL) in Diffuse Axonal Injury Patients
Times Control (n = 16)mean
± SEM, ng/ml
Progesterone (n = 16)
mean± SEM, ng/ml
Admission time 15.41± 0.85 14.42± 0.88
24 hours after injury 14.83± 0.87 14.09± 0.99
6 days after injury 2.14± 0.21a , b 5.63± 1.67a , b
aP < 0.01 vs. admission in the control or progesterone group.
bP < 0.01 vs. 24 hours after injury in the control or progesterone group.
serum levels of ICAM-1 and NSE in DAI patients. The main
findings of this study were: 1, the serum level of ICAM-1 re-
duced remarkably in DAI patients following progesterone
administration 24 h after injury; 2, progesterone did not
change the serum level of NSE in DAI patients during eval-
uation.
The authors of this study have begun to examine the ef-
fect of progesterone as a therapeutic agent in clinical DAI
by trying to account for their experimental studies (4, 5).
They have reported that progesterone administration can
cause the improvement of neurologic outcome in DAI pa-
tients (19).
Brain-related proteins are appeared in the systemic cir-
culation following BBB disruption (20). Serum biomark-
ers in TBI are a useful means for evaluating the condition
(21). Also, the assessment of TBI biomarkers improves the
development of an individualized treatment (1). Studies
have consistently demonstrated that progesterone, as a
neurosteroid with multiple functions, modulates diverse
secondary injury mechanisms in TBI, including apoptotic
pathways, diffuse axonal injury, stress oxidative (4, 22),
and the expression of inflammatory cytokines (3, 17). We
have previously reported decreasing S100 calcium-binding
protein B (S-100 B), IL-1β and MDA and increasing TGF-β1
Arch Trauma Res. 2016; 5(3):e37005. 3
Shahrokhi N et al.
and IL-6 in serum associated to improving neurologic out-
come in progesterone-administered DAI patients (19). In
the present study, the effect of progesterone administra-
tion on the serum levels of ICAM-1 and NSE in DAI patients
was determined.
In current study, the serum level of ICAM-1 reached to
peak 24 hours after DAI and returned to the control level
6 days after DAI. Progesterone prevented the increase in
ICAM-1 24 hours after DAI. The expression of IL-1β, TNF-α
and IL-6, and ICAM-1 in the injured brain up-regulates in TBI
(16, 17). Activated astrocytes and microglia release a num-
ber of pro-inflammatory mediators that could contribute
to secondary phase brain injury (23). Neuroinflammatory
factors increase after TBI and likely contribute to oxidative
stress and neuronal death, which in turn further exacer-
bate the inflammatory response (24). The BBB destruction
in TBI is associated with serum level of ICAM-1 (25).
The effect of progesterone on the serum level of ICAM-
1 in the present study is consistent with studies that the
ICAM-1 reduced in rats with brain injury following pro-
gesterone (16, 17). Also, progesterone decreased the in-
flammatory response and the leukocytes infiltration in
the ischemic brain by inhibiting the expression of ICAM-1
(26). To the best of our knowledge, there has not yet been
any contrary study assessing the effect of progesterone on
ICAM-1 level in brain injury. The results of previous (19)
and present studies confirm that a high level of adhesion
molecules in TBI patients is associated with poor outcome
(27).
In the current study, progesterone treatment did not
alter the serum level of NSE that may be due to a num-
ber of reasons including dose and duration of the proges-
terone treatment or not targeted these parameters by pro-
gesterone that requires further exploration. To the best of
our knowledge, there has not yet been any study assessing
the effect of progesterone on the NSE level in brain injury.
The increase in the NSE concentration could be an indica-
tion of inflammatory response after TBI (28). The relation
of the NSE level in serum with outcome has been shown
in 72 h postinjury, probably because of its short half-life
(29). The increase in the serum level of NSE was associated
to favorable outcome in other study (30). However, previ-
ous (19) and present studies indicate that the serum level
of NSE is not different between patients with favorable out-
come and those with unfavorable outcome. It is postu-
lated that the difference between results may be due to the
timing schedule used for taking blood samples. Also, in a
study, early elevation in the CSF level of NSE in patients with
severe TBI was able to predict those patients who would in-
volve to brain death from those who would survive (31). It is
mentioned that injury severity of the patients in our study
was not severe.
Progesterone may act on inflammation both directly
(32) and indirectly by the modulation of toll-like recep-
tors and NF-κB signaling with a concurrent reduction in
cytokines (33). NF-κB is a transcriptional factor required
for the gene expression of many inflammatory mediators,
such as IL-1β, IL-6 and ICAM-1 (17). The inhibition of NF-kB
activation may provide a pharmacological agent against
the pathological inflammatory conditions (34). The down-
regulation of NF-kB has been reported by progesterone at 5
days postinjury (16). So, progesterone may decrease ICAM-
1 by suppressing the NF-kB activation. The exact mecha-
nisms remain unclear.
Therefore, progesterone may attenuate the devel-
opment of secondary brain damage following primary
trauma in part by decreasing ICAM-1. The latter may be one
of the anti-inflammatory mechanisms of progesterone
that needs further investigations for confirmation. An as-
sociation of ICAM-1 and NSE to neurologic outcome in DAI
also needs to be further studied.
5.1. Limitations
Our study has a number of limitations that should be
considered. First, sample size of the study was small that
can cause type II error. Second, the current study was lim-
ited to adults, whereas the TBI is also a very common occur-
rence in pediatric patients.
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